GSK PLC Stock Price, News & Analysis

GSK Consumer Healthcare (GSK) announced a partnership with MLB champion Cody Bellinger as the face of its 'Change The Game' campaign for Flonase Allergy Relief. As the Official Allergy Relief Partner of MLB, Flonase targets allergy sufferers, highlighted by Bellinger, who deals with seasonal allergies during baseball season. The campaign will feature baseball-themed marketing across various media. Bellinger emphasizes the effectiveness of Flonase in managing his symptoms, advocating a 100% Money Back Guarantee for consumers.

GSK Consumer Healthcare (GSK) announced a partnership with MLB and World Series champion Cody Bellinger to promote Flonase Allergy Relief through the "Change The Game" campaign. As the Official Allergy Relief Partner of MLB, Flonase aims to address allergy challenges faced by athletes and fans, especially during baseball season. Bellinger, who suffers from seasonal allergies, emphasizes switching to Flonase for 24-hour relief. The campaign will leverage baseball-themed marketing across digital and retail channels, along with a 100% Money Back Guarantee for consumers.

Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced promising topline results from the Phase 2 BLAZE-4 trial, showing that the combination of bamlanivimab and VIR-7831 significantly reduced high viral loads in low-risk COVID-19 patients by 70% at day 7 compared to placebo. No related hospitalizations or deaths occurred by day 29. Preclinical data suggest the combination can combat resistant SARS-CoV-2 variants. An Emergency Use Authorization application for VIR-7831 has been submitted to the FDA, aiming to expedite its availability for COVID-19 treatment.

GSK Consumer Healthcare (GSK) announced the launch of TUMS Naturals, a new antacid that caters to consumer preferences for natural ingredients. This product expands TUMS' portfolio, which is the top heartburn relief medicine in the U.S., by offering alternatives free from artificial flavors and dyes. TUMS Naturals, containing Calcium Carbonate, is available in two fruity flavors and is designed to neutralize stomach acid quickly. The product aligns with consumer demand for natural health solutions and aims to provide effective relief from heartburn without compromising on quality.

GlaxoSmithKline (GSK) has launched the #TUMSBingoSweepstakes, an engaging digital bingo game coinciding with the BIG GAME on February 7, 2021. Participants can win a share of $55,000 in prizes, with the grand prize being $35,000. The game celebrates moments that induce heartburn, allowing fans to interactively enjoy the event. TUMS aims to combine entertainment with heartburn relief, with digital game boards updating in real-time during the game. This initiative follows their successful 2020 sweepstakes and aims to enhance viewer participation.

Eli Lilly (LLY), Vir Biotechnology (VIR), and GlaxoSmithKline (GSK) announced a collaboration to evaluate the combination of their COVID-19 therapies in low-risk patients with mild to moderate COVID-19. The expanded BLAZE-4 trial will assess bamlanivimab (700mg) with VIR-7831 (500mg), both neutralizing antibodies targeting SARS-CoV-2. This marks the first cross-company monoclonal antibody collaboration. Bamlanivimab is authorized for emergency use, while VIR-7831 is investigational. The trial aims to determine if this combination therapy can improve treatment outcomes.

Eligo Bioscience has signed a research and option agreement with GlaxoSmithKline (GSK) to advance its breakthrough treatment, EB005, targeting acne vulgaris through CRISPR-based technology. Eligo will receive an upfront payment and funding to progress EB005 until preclinical proof of concept. If GSK opts in, Eligo could earn up to $224 million in fees and milestone payments, plus royalties on sales. The partnership aims to address acne's root causes by selectively modulating the skin's microbiome, potentially changing treatment paradigms in the industry.

GSK has received FDA approval for BENLYSTA (belimumab) to treat adult patients with active lupus nephritis (LN) in conjunction with standard therapy. This marks a significant advancement as BENLYSTA is the first approved medication for this condition in over 50 years. The approval, based on the successful BLISS-LN study, showed 43% of patients treated with BENLYSTA achieved Primary Efficacy Renal Response compared to 32% with placebo. The treatment aims to improve renal outcomes and delay kidney replacement therapies, addressing a critical need in the lupus community.